Editorial Board
(Source: Lung Cancer)
Source: Lung Cancer - September 20, 2020 Category: Cancer & Oncology Source Type: research

Contents
(Source: Lung Cancer)
Source: Lung Cancer - September 20, 2020 Category: Cancer & Oncology Source Type: research

Prognostic significance of spread through air spaces in pulmonary metastases from colorectal cancer
Surgical resection for pulmonary metastases from colorectal cancer (PM-CRC) has been found to be associated with prolonged relapse-free survival, and it has been considered a practical standard therapy [1,2]. According to a systematic review of patients undergoing pulmonary metastasectomy for CRC, the median 5-year overall survival (OS) was 52.5 % [3]. Along with the development of molecular targeted therapy, 5-year OS has improved to more than 70 % in the last decade [4]. Completeness of resection is a known predictor of survival, as well as size and number of PM, intrathoracic lymph node involvement, pre-metastasectomy s...
Source: Lung Cancer - September 20, 2020 Category: Cancer & Oncology Authors: Naoko Takeda-Miyata, Eiichi Konishi, Tadashi Tanaka, Masanori Shimomura, Hiroaki Tsunezuka, Satoru Okada, Shunta Ishihara, Narumi Ishikawa, Masayoshi Inoue Source Type: research

Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study
Obesity is responsible for multiple chronic diseases, including type 2 diabetes, hypertension, coronary artery disease, stroke, and several types of cancer [1]. The body mass index (BMI) —as an easy-to obtain, acceptable proxy for thinness and fatness—has been found to be associated with health risk and death in many populations. According to the World Health Organization definition, the normal range of BMI is defined as 18.5 to (Source: Lung Cancer)
Source: Lung Cancer - September 19, 2020 Category: Cancer & Oncology Authors: Koichi Fukumoto, Shoichi Mori, Yasushi Shintani, Jiro Okami, Hiroyuki Ito, Takashi Ohtsuka, Shinichi Toyooka, Takeshi Mori, Shun-ichi Watanabe, Hisao Asamura, Masayuki Chida, Hiroshi Date, Shunsuke Endo, Takeshi Nagayasu, Ryoichi Nakanishi, Etsuo Miyaoka, Source Type: research

Everolimus in the treatment of metastatic thymic epithelial tumors
Optimal treatment in the relapsed-refractory setting for patients with advanced thymic epithelial tumors (TETs) is poorly understood. The current standard of care first line treatment for advanced thymoma and thymic carcinoma is a platinum-based regimen based on data from several small single-arm phase 2 studies. Cyclophosphamide/doxorubicin/cisplatin (CAP) and carboplatin/paclitaxel are both options for TETs, although the former is more commonly used for advanced thymoma [1,2] and the latter for thymic carcinoma [3]. (Source: Lung Cancer)
Source: Lung Cancer - September 17, 2020 Category: Cancer & Oncology Authors: Jessica A. Hellyer, Madhu M. Ouseph, Sukhmani K. Padda, Heather A. Wakelee Source Type: research

Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14 –skipping mutation: A series of 6 cases
The prognosis of advanced non-small –cell lung cancer (NSCLC) has been dramatically improved by promising new treatments: targeted therapies for oncogenic addictions and immune-checkpoint inhibitors (ICIs), including anti-programmed cell-death protein-1 (PD-1) nivolumab and pembrolizumab. (Source: Lung Cancer)
Source: Lung Cancer - September 16, 2020 Category: Cancer & Oncology Authors: Marie Mayenga, Jean-Baptiste Assi é, Isabelle Monnet, Marie-Ange Massiani, Laure Tabeze, Sylvie Friard, Séverine Fraboulet, Anne-Cécile Métivier, Christos Chouaïd, Leïla Zemoura, Elisabeth Longchampt, Céline Callens, Samia Melaabi, Louis-Jean Coude Source Type: research

Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India
Epidermal growth factor receptor (EGFR) mutations are one of the best characterized driver mutations in primary lung adenocarcinomas (ADCAs), a subtype of non-small-cell lung cancer (NSCLC) [1 –3]. The mutations occur in a hotspot spanning exons 18–21 encoding the tyrosine kinase domain (TKD) of the EGFR gene, resulting in a mutant EGFR protein that is constitutively activated, leading to tumorigenesis. Small-molecule tyrosine kinase inhibitors (TKIs) competitively inhibit the binding of adenosine triphosphate to the intracellular kinase domain of the mutant EGFR protein, blocking its constitutive activation. (Source: Lung Cancer)
Source: Lung Cancer - September 12, 2020 Category: Cancer & Oncology Authors: Varsha Singh, Aruna Nambirajan, Prabhat Singh Mailk, Sanjay Thulkar, Ravindra Mohan Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Anant Mohan, Deepali Jain Source Type: research

Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression
Treatment options have evolved in advanced Non-Small-Cell Lung Cancer (NSCLC) during the last decades with introduction of immunotherapy and targeted treatments. The understanding that molecular characteristics and tumor biology is dynamic - and also influenced by treatment and resistance mechanisms - has raised an emerging debate about how monitoring of tumor biology should be performed. The introduction of immune-checkpoint inhibitor therapies in NSCLC in both first and further lines of treatment has increased the focus on potential changes in the predictive biomarker PD-L1 during treatment and the potential clinical imp...
Source: Lung Cancer - September 12, 2020 Category: Cancer & Oncology Authors: Malene St øchkel Frank, Uffe Bodtger, Asbjørn Høegholm, Inger Merete Stamp, Julie Gehl Source Type: research

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study
Approximately two-thirds of patients who present with small-cell lung cancer (SCLC) have extensive-stage SCLC (ES-SCLC), reflecting the highly aggressive nature of this tumor and its tendency for early, widespread metastasis [1,2]. Less than 5% of patients with ES-SCLC remain alive at 2 years after diagnosis [3]. Progress in improving outcomes for patients with ES-SCLC has been limited until recently. Standard first-line treatment has consisted of etoposide in combination with either carboplatin or cisplatin (EP) for more than three decades [4 –6]. (Source: Lung Cancer)
Source: Lung Cancer - September 10, 2020 Category: Cancer & Oncology Authors: Jonathan W. Goldman, Marina Chiara Garassino, Yuanbin Chen, Mustafa Özgüroğlu, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Katsuyuki Hotta, Jun Ho Ji, Maximilian J. Hochmair, Oleksandr Voitko, Libor Havel, Artem Poltoratskiy, György Losonczy, N Source Type: research

KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma
KRAS oncogene is known as an “undruggable” target for decades, the mutation rate is about 20-25% in non-small cell lung cancer(NSCLC) [1]. Recently, preliminary data from a phase I clinical trial of the KRAS G12C inhibitor AMG510 were reported, showing the potential anti-tumor activity of AMG 510 as a monotherapy in NSCLC[2 ]. As the first KRAS agents to process and enter clinical trials, AMG510 undoubtedly breaks the "curse" and brings hope to patients with KRAS mutation. However, AMG510 is still in the early phase of clinical experiment, besides G12C is only one of the mutation subtypes in KRAS, opt...
Source: Lung Cancer - September 10, 2020 Category: Cancer & Oncology Authors: Ge Gao, Weiting Liao, Qizhi Ma, Benxia Zhang, Yue Chen, Yongsheng Wang Source Type: research

ERK Phosphorylation as a Marker of RAS Activity and its Prognostic Value in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. Recent improvements have been achieved by refined staging and surgical techniques in early stage disease, and the introduction of targeted therapies and immune checkpoint inhibitors in patients with metastatic NSCLC. Nevertheless, long-term survival is only achieved in a minority of patients with advanced or recurrent disease. Activation of intracellular signaling pathways are key determinants in tumor proliferation, treatment response, and resistance. (Source: Lung Cancer)
Source: Lung Cancer - September 10, 2020 Category: Cancer & Oncology Authors: Timm M. Reissig, Linda Sara, Saskia Ting, Henning Reis, Martin Metzenmacher, Wilfried E.E. Eberhardt, Gregor Zaun, Thomas Herold, Clemens Aigner, Kaid Darwiche, Martin Stuschke, Hans-Ulrich Schildhaus, Martin Schuler, Marcel Wiesweg Source Type: research

Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer
(Source: Lung Cancer)
Source: Lung Cancer - September 9, 2020 Category: Cancer & Oncology Authors: Xiaoke Liu, Lingzhi Hong, Monique Nilsson, Shawna Marie Hubert, Shuhong Wu, Waree Rinsurongkawong, Jeffery Lewis, Amy Spelman, Jack Roth, Steven Swisher, Yong He, J. Jack Lee, Bingliang Fang, John V. Heymach, Jianjun Zhang, Xiuning Le Source Type: research

Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma
Stevens-Johnsons syndrome (SJS) is a rare but life-threatening cutaneous adverse reaction mainly elicited by exposure to certain drugs, including epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and immunotherapies [1 –3]. Nivolumab has been widely used for treating lung cancer and has been reported to cause this devastating adverse event and warrants permanent medication termination [4]. Nevertheless, immunotherapy itself may not always be the culprit medication but, rather, might simply be an enhancer of immu nologic reactions in another drug-induced SJS. (Source: Lung Cancer)
Source: Lung Cancer - September 5, 2020 Category: Cancer & Oncology Authors: Yi-Tsz Lin, James Chih-Hsin Yang, Chia-Yu Chu Source Type: research

Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients
Tumor mutational burden (TMB), defined as the total number of somatic mutations per tumor genome, is a known predictive biomarker for immune checkpoint inhibitor (ICI) therapy outcome, following the observation that high TMB associates with positive treatment response[1 –6]. Accurate TMB estimation has proven to be challenging at both the pre-analytical and analytical stage, potentially leading to contradictory results across different studies regarding the predictive value of TMB[7]. Thus, understanding the complexity of TMB applications is of great clinical rel evance. (Source: Lung Cancer)
Source: Lung Cancer - September 5, 2020 Category: Cancer & Oncology Authors: Ilaria Alborelli, Ivana Bratic Hench, Obinna Chijioke, Spasenija Savic Prince, Lukas Bubendorf, Laura P. Leuenberger, Markus Tolnay, Katharina Leonards, Luca Quagliata, Philip Jermann, Matthias S. Matter Source Type: research

Characteristics and Response to Crizotinib in Lung Cancer Patients with MET Amplification Detected by Next-Generation Sequencing
Mesenchymal-epithelial transition (MET) is a proto-oncogene located on chromosome 7q21-31 that encodes a transmembrane tyrosine kinase receptor for hepatocyte growth factor (HGF) [1,2]. In lung cancer, mechanisms of MET pathway activation include MET overexpression and genetic alteration such as MET mutation or amplification [3]. A previous study reported that in epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma samples, MET amplification was found in 21% of patients with acquired resistance to EGFR- tyrosine kinase inhibitors (TKI) and 3% of untreated patients [4]. (Source: Lung Cancer)
Source: Lung Cancer - September 5, 2020 Category: Cancer & Oncology Authors: Jingwen Li, Yue Wang, Bo Zhang, Jianlin Xu, Shuhui Cao, Hua Zhong Source Type: research

Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ
Whether malignant mesothelioma has an in situ phase has long been a controversy [1]. Until recently the consensus was that mesothelioma in situ (MIS) cannot be separated from reactive surface mesothelial proliferations on morphology alone. However, the concept of MIS was recently reintroduced for surface, usually flat or simple papillary, mesothelial proliferations with loss of BAP1 nuclear staining by immunohistochemistry occurring in patients with unexplained recurrent effusions in the absence of radiologic or clinical gross evidence of the disease [2 –4]. (Source: Lung Cancer)
Source: Lung Cancer - September 5, 2020 Category: Cancer & Oncology Authors: Sanja Dacic, Somak Roy, Maureen A. Lyons, Jan H. von der Thusen, Francoise Galateau-Salle, Andrew Churg Source Type: research

Radiation Pneumonitis after Definitive Chemoradiation and Durvalumab for Non-Small Cell Lung Cancer
Pneumonitis is an uncommon but potentially fatal adverse event of both radiotherapy (RT) [1] and anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC. [2] Symptomatic radiation (RT-) pneumonitis following chemoradiation can occur in up to 30% of patients, with 1%-16% of them requiring supplemental oxygen and 2% resulting in death. [3 –5] The incidence of ICI-related (ICI-) pneumonitis following anti-PD-1/PD-L1 monotherapy or combinations, ranges from 1%-10%. [6,7] Recently, the addition of 1 year of maintenance anti-PD-L1 therapy after definitive chemoradiation has become a...
Source: Lung Cancer - September 4, 2020 Category: Cancer & Oncology Authors: Khinh Ranh Voon, Jarushka Naidoo Tags: Editorial Source Type: research

European Cancer Organisation Essential Requirements for Quality Cancer Care: Lung cancer
There has been a growing emphasis on improving quality in cancer organisations given variations in outcomes in Europe. The European Cancer Concord (ECC), a partnership of patients, advocates and cancer professionals, recognised major disparities in the quality of cancer management and in the degree of funding in Europe. Its European Cancer Patient ’s Bill of Rights is a patient charter that underpins equitable access to optimal cancer control, cancer care and research for Europe’s citizens. [1] (Source: Lung Cancer)
Source: Lung Cancer - September 3, 2020 Category: Cancer & Oncology Authors: Thierry Berghmans, Yolande Lievens, Matti Aapro, Anne-Marie Baird, Marc Beishon, Fiorella Calabrese, Csaba D égi, Roberto C. Delgado Bolton, Mina Gaga, József Lövey, Andrea Luciani, Philippe Pereira, Helmut Prosch, Marika Saar, Michael Shackcloth, Geer Tags: Review Source Type: research

Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
(Source: Lung Cancer)
Source: Lung Cancer - September 2, 2020 Category: Cancer & Oncology Authors: Filippo G. Dall ’Olio, Nicole Conci, Giulio Rossi, Michelangelo Fiorentino, Andrea De Giglio, Giada Grilli, Annalisa Altimari, Elisa Gruppioni, Daria M. Filippini, Alessandro Di Federico, Andrea Ardizzoni Source Type: research

Editorial Board
(Source: Lung Cancer)
Source: Lung Cancer - September 1, 2020 Category: Cancer & Oncology Source Type: research

Contents
(Source: Lung Cancer)
Source: Lung Cancer - September 1, 2020 Category: Cancer & Oncology Source Type: research

Targeting polyamine as a novel therapy in xenograft models of malignant pleural mesothelioma
(Source: Lung Cancer)
Source: Lung Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Sze-Kwan Lam, Sheng Yan, Shi Xu, James Chung-Man Ho Source Type: research

Nationwide effect of high procedure volume in lung cancer surgery on in-house mortality in Germany
Lung cancer is the number one cause of cancer deaths worldwide and treatment is expensive [1]. First-line therapy in early-stage lung cancer is surgical resection if appropriate from a technical and oncological perspective [2]. High variability in operative mortality and morbidity have been reported, and these characteristics are an indicator of poor-quality surgical care [3]. Treatment at high-volume hospitals is related to improved perioperative and postoperative outcomes, especially from United States ’ data [4–7]. (Source: Lung Cancer)
Source: Lung Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Philip Baum, Johannes Diers, Johannes Haag, Laura Klotz, Florian Eichhorn, Martin Eichhorn, Armin Wiegering, Hauke Winter Source Type: research

Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis, clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
(Source: Lung Cancer)
Source: Lung Cancer - August 23, 2020 Category: Cancer & Oncology Authors: Xiangling Chu, Jing Zhao, Juan Zhou, Fei Zhou, Tao Jiang, Sen Jiang, Xiwen Sun, Xiaofang You, Wu Fengying, Shengxiang Ren, Caicun Zhou, Chunxia Su Source Type: research

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing
(Source: Lung Cancer)
Source: Lung Cancer - August 21, 2020 Category: Cancer & Oncology Authors: P. Christopoulos, M. Kirchner, J. Roeper, F. Saalfeld, M. Janning, F. Bozorgmehr, N. Magios, D. Kazdal, A. Volckmar, L.M. Br ückner, T. Bochtler, M. Kriegsmann, V. Endris, R. Penzel, K. Kriegsmann, M. Eichhorn, F. Herth, C.P. Heussel, R. El Shafie, M. Sc Source Type: research

Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer
(Source: Lung Cancer)
Source: Lung Cancer - August 21, 2020 Category: Cancer & Oncology Authors: Kenichi Suda, Isao Murakami, Keiko Obata, Kazuko Sakai, Toshio Fujino, Takamasa Koga, Shuta Ohara, Akira Hamada, Junichi Soh, Kazuto Nishio, Tetsuya Mitsudomi Source Type: research

The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients
Clinical auditing proved to be a valuable process for the improvement of medical care and patient outcomes[1]. The use of quality registries or clinical audits has been effective in the last decade in evaluating and improving medical care by minimizing undesired practice variation and improving patient outcomes. National audits for lung cancer patients included mostly surgical treatment of lung cancer[2 –4]. (Source: Lung Cancer)
Source: Lung Cancer - August 21, 2020 Category: Cancer & Oncology Authors: R.K. Ismail, F.M.N.H. Schramel, M. van Dartel, D.L. Hilarius, A. de Boer, M.W.J.M. Wouters, H.J.M. Smit, on behalf of the Dutch Lung Cancer Audit Scientific Committee Source Type: research

Primary Resistance to Gefitinib in a Patient with Lung Adenocarcinoma Harboring an EGFR Exon 19 L747-A750 > P Mutation
This study is the first to report a patient with lung adenocarcinoma harboring an EGFR Ex19Del mutant L747-A750>P who presented with primary resistance to gefitinib. (Source: Lung Cancer)
Source: Lung Cancer - August 20, 2020 Category: Cancer & Oncology Authors: Qiang Wei, Jin Zhang, Dongsheng Chen, Si Li, Yuanhua Liu Source Type: research

Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy
Thymic carcinoma is a rare cancer that is regarded as a model for “major” rare cancers, with several prospective clinical trials aimed at developing pharmacotherapy options having been performed; thus, limited evidence for guidelines based on retrospective studies and single-arm phase II studies with small sample sizes has been accumulated over time [1]. In Ja pan, the number of annual deaths from thymic malignancies was reported to be 418 patients in 2017 [2]. An update of the UICC classification for thoracic malignances, including thymoma and thymic carcinoma, is an ongoing and international challenge that ha...
Source: Lung Cancer - August 20, 2020 Category: Cancer & Oncology Authors: Yusuke Okuma, Ryo Ko, Takeito Shukuya, Kazunari Tateishi, Hisao Imai, Shunichiro Iwasawa, Eisaku Miyauchi, Tetsuya Kojima, Yuka Fujita, Toshihiko Hino, Shinsuke Yamanda, Toshiro Suzuki, Aya Fukuizumi, Toshihiro Sakakibara, Toshiyuki Harada, Satoshi Morita Source Type: research

Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis
Lung cancer remains one of the most common cancers, resulting in 1.76 million deaths worldwide in 2018 [1]. Risk factors of lung cancer include tobacco smoking, environment tobacco smoke (passive smoking), occupational exposures, air pollution, diet such as red meat, previous respiratory diseases, and genetic susceptibility [2 –4]. Tobacco smoking was identified as the major risk factor for lung cancer, however, despite successful efforts to reduce tobacco smoking, there was no significant reduction in lung cancer cases globally in the past decade [3,5]. (Source: Lung Cancer)
Source: Lung Cancer - August 20, 2020 Category: Cancer & Oncology Authors: Lina Ang, Cheryl Pui Yi Chan, Wai-Ping Yau, Wei Jie Seow Source Type: research

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers
(Source: Lung Cancer)
Source: Lung Cancer - August 18, 2020 Category: Cancer & Oncology Authors: Haiyan Yang, Zhen Zhou, Li Lin, Mingxia Yang, Chong Li, Ziming Li, Xinmin Yu, Analyn Lizaso, Han Han-Zhang, Bing Li, Jianxing Xiang, Xinru Mao, Qinqin Xu, Yongchang Zhang, Nong Yang Source Type: research

Stereotactic radiosurgery for brain metastases: A retrospective cohort study comparing treatment results between two lung cancer patient age groups, 75 years or older vs 65 –74 years
(Source: Lung Cancer)
Source: Lung Cancer - August 17, 2020 Category: Cancer & Oncology Authors: Masaaki Yamamoto, Toru Serizawa, Yasunori Sato, Yoshinori Higuchi, Hidetoshi Kasuya, Bierta E. Barfod Source Type: research

Novel imprint cytological classification is correlated with tumor spread through air spaces in lung adenocarcinoma
The concept of spread through air spaces (STAS) was introduced in the 2015 World Health Organization Classification of non-small cell lung cancer. STAS was shown to be a prognostic factor for poor outcomes after sublobar resection in patients with lung cancer [1,2]; therefore, intraoperative evaluation of the presence of STAS is considered to be important, especially for intentional limited resection of small pulmonary nodules under 2  cm in size. However, diagnosis based on the findings of intraoperative frozen section analysis, the most common method of histological evaluation of tumors, is reported to be difficul...
Source: Lung Cancer - August 11, 2020 Category: Cancer & Oncology Authors: Toru Kimura, Harumi Nakamura, Akiisa Omura, Akihiro Ike, Takashi Hiroshima, Tomohiro Maniwa, Keiichiro Honma, Masahiko Higashiyama, Jiro Okami Source Type: research

Exploring imaging features of molecular subtypes of large cell neuroendocrine carcinoma (LCNEC)
Large cell neuroendocrine carcinoma (LCNEC) of the lung is a rare tumor type, representing 1-3% of all types of lung cancer [1,2]. The histological diagnosis of LCNEC is complex, and preferably, surgical resected tumor tissue is used [3]. LCNEC can be separated in two main molecular subtypes: the first is SCLC-like (pathological SCLC-like, pSCLC-like), with co-mutation of RB1 and TP53 and loss of immunohistochemical (IHC) pRb expression and the second is NSCLC-like (pNSCLC-like), with co-mutation of TP53 and STK11/KEAP1/KRAS genes and preserved pRb expression [4 –6]. (Source: Lung Cancer)
Source: Lung Cancer - August 11, 2020 Category: Cancer & Oncology Authors: B.C.M. Hermans, S. Sanduleanu, J.L. Derks, H. Woodruff, L. Hillen, R. Casale, F. Mohamed Hoesein, E. de Jong, D.M.H.J. ten Berge, E.J.M. Speel, P. Lambin, H.A. Gietema, A-M.C. Dingemans Source Type: research

A reply to “Comment on: ‘Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer”
We would like to thank Yuji Inagaki and Akihiro Tamiya for their comment on our recent publication ‘Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer’. (Source: Lung Cancer)
Source: Lung Cancer - August 8, 2020 Category: Cancer & Oncology Authors: Bianca van Veggel, Adrianus Johannes de Langen Source Type: research

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy
adverse drug reaction (Source: Lung Cancer)
Source: Lung Cancer - August 8, 2020 Category: Cancer & Oncology Authors: Martin Reck, Kostas Syrigos, Skaidrius Miliauskas, Sabine Z öchbauer-Müller, Jürgen R. Fischer, Hannes Buchner, Thomas Kitzing, Rolf Kaiser, Dejan Radonjic, Keith Kerr Source Type: research

Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms
The prognosis and therapeutic strategy of lung neuroendocrine neoplasms (NENs) depend on the clinical features of the patients and the accurate characterization of the tumor [1,2]. The World Health Organization (WHO) 2015 classification of lung NENs identifies four distinct categories: typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). This classification relies on three histological criteria: (a) the morphological differentiation status, based on architectural and cytological features, (b) the mitotic count (MC), evaluated by counting the numb...
Source: Lung Cancer - August 7, 2020 Category: Cancer & Oncology Authors: M. Rubino, J.Y. Scoazec, E. Pisa, M. Faron, L. Spaggiari, J. Hadoux, F. Spada, D. Planchard, C.A. Cella, S. Leboulleux, F. De Marinis, M. Ducreux, L. Lamartina, E. Baudin, N. Fazio Source Type: research

Proposal of organ-specific subdivision of M component and staging system for metastatic pulmonary neuroendocrine tumor
Recently, with improvement of diagnostic methods, the incidence rate of neuroendocrine tumors (NETs) has increased[1]. Aside from NETs located in gastrointestinal (GI) tract, those originated from lungs and bronchi are common[2]. In the 2015 WHO pathologic classification, according to the mitotic count and presence of necrosis, pulmonary neuroendocrine tumors (PNETs) are divided into typical carcinoid (TC), atypical carcinoid, large cell neuroendocrine carcinoma and small cell carcinoma[3]. However, it was not until 2010 that the American Joint Committee on Cancer (AJCC) introduced its first tumor-node-metastases (TNM) sta...
Source: Lung Cancer - August 7, 2020 Category: Cancer & Oncology Authors: Junmiao Wen, Jiayan Chen, Di Liu, Donglai Chen, Yongbing Chen, Min Fan, Bo Lu Source Type: research

Improving Identification of Candidates for Lung Cancer Screening in a High Risk Population
Lung cancer is the third most common cancer in the United States with an estimated 234,000 predicted cases in 2018, of which approximately 85% are attributable to smoking.1,2 Since lung cancer is commonly asymptomatic until an advanced stage, 75% of patients present with locally advanced or incurable metastatic disease.2 Advanced stage disease at presentation coupled with the natural biology of the disease and the high prevalence of disease contributes to lung cancer persistently causing most cancer-related deaths in the US with approximately 154,000 deaths each year. (Source: Lung Cancer)
Source: Lung Cancer - August 6, 2020 Category: Cancer & Oncology Authors: Mark R. Waddle, Stephen Ko, Jackson May, Tasneem Kaleem, Daniel Miller, William Stross, Timothy Malouff, Katey Wert, Kristin uthbert, Robin Landy, Gerald Strong, Laura A. Vallow, Margaret M. Johnson Source Type: research

Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling
Tissue-based testing for predictive biomarkers to guide selection of matched targeted therapy is standard-of-care in advanced non-small cell lung cancer (NSCLC)[1]. Genomic biomarkers for Food and Drug Administration (FDA)-approved therapies in NSCLC include EGFR activating mutations, EGFR T790  M, BRAF V600E, rearrangements in ALK or ROS1, and more recently pan-tumor approvals for NTRK1-3 rearrangements and high microsatellite instability (MSI-H). National Comprehensive Cancer Network (NCCN) NSCLC clinical practice guidelines additionally suggest testing for emerging biomarkers includin g RET rearrangement, MET exo...
Source: Lung Cancer - August 5, 2020 Category: Cancer & Oncology Authors: Russell Madison, Alexa B. Schrock, Emily Castellanos, Jeffrey P. Gregg, Jeremy Snider, Siraj M. Ali, Vincent A. Miller, Gaurav Singal, Brian M. Alexander, Jeffrey M. Venstrom, Jon H. Chung Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer
According to GLOBOCAN 2018, lung cancer is the leading cause of new cancer cases and cancer-related deaths. Worldwide, 2.1 million new lung cancer cases and 1.8 million deaths were reported in 2018 [1]. More than 80% of these cases are Non-small cell lung cancer (NSCLC), and almost the same percentage of tumours are high stage (Stage III and IV) [2]. About 30-40% of stage IV NSCLC patients develop central nervous system (CNS) disease [3,4]. Overall, 1-5% of NSCLC patients have leptomeningeal (LM) involvement [5]. (Source: Lung Cancer)
Source: Lung Cancer - August 5, 2020 Category: Cancer & Oncology Authors: Moushumi Suryavanshi, Jiten Jaipuria, Manoj Kumar Panigrahi, Neha Goyal, Rishu Singal, Anurag Mehta, Ullas Batra, DC Doval, Vineet Talwar Source Type: research

ROS1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis
In the article published by Zhou et al. [1], it was identified a novel ROS1 mutation type namely G2032  K in which mediated resistance to targeted therapy like lorlatinib in lung adenocarcinoma. They suggested that immune checkpoint inhibitors (ICIs) plus chemotherapy could be considered as an option for patients harboring ROS1 mutations after acquired resistance to targeted therapies. Nevertheless , it was unknown whether the patient with ROS1 mutations would obtain clinical benefit from ICIs treatment alone. (Source: Lung Cancer)
Source: Lung Cancer - August 4, 2020 Category: Cancer & Oncology Authors: Xuanzong Li, Linlin Wang, Jinming Yu Source Type: research

Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient
Cancer evolves from a single cell that undergoes transformation and acquires a strong proliferative capacity through several genetic alterations, including somatic mutations, chromosomal copy-number alterations, dynamic changes in chromosome number and structure, and epigenetic instability (1,2). Cancer founder cells are characterized by a strong proliferative capacity; thus, they expand to compete with neighboring normal cells. This expansion is influenced by the surrounding tumor microenvironment, including the immune system (3,4). (Source: Lung Cancer)
Source: Lung Cancer - August 2, 2020 Category: Cancer & Oncology Authors: Kei Kunimasa, Yosuke Hirotsu, Yoshihiro Miyashita, Taichiro Goto, Kenji Amemiya, Hitoshi Mochizuki, Ikuko Samamoto, Takamasa Ohki, Toshio Oyama, Keiichiro Honma, Fumio Imamura, Kazumi Nishino, Toru Kumagai, Masao Omata Source Type: research

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients
Similar to the advent of target therapy, immune checkpoint inhibitors (ICIs) are rapidly shifting the oncological landscape and profoundly transforming clinical cancer care, in particular in non-small cell lung cancer (NSCLC) [1,2]. (Source: Lung Cancer)
Source: Lung Cancer - August 2, 2020 Category: Cancer & Oncology Authors: G. Mazzaschi, R. Minari, A. Zecca, A. Cavazzoni, V. Ferri, C. Mori, A. Squadrilli, P. Bordi, S. Buti, M. Bersanelli, A. Leonetti, A Cosenza, L. Ferri, E. Rapacchi, G. Missale, P.G. Petronini, F. Quaini, M Tiseo Source Type: research

Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE)
Stage III locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous condition affecting about one-third of the overall patients (1). Usually, therapeutic approach consists of a combination of local therapy (radiotherapy) with systemic platinum-based doublet chemotherapy. However, the prognosis remains poor, with only a limited improvement in survival achieved over the past 10 years. Recently, it has been shown that durvalumab significantly prolonged progression-free and overall survival, as compared with placebo, among patients with unresectable stage III NSCLC after concurrent chemoradiotherapy (2 –3). ...
Source: Lung Cancer - August 2, 2020 Category: Cancer & Oncology Authors: Alessandro Marchioni, Dario Andrisani, Roberto Tonelli, Roberto Piro, Alessandro Andreani, Gaia Francesca Cappiello, Emmanuela Meschiari, Massimo Dominici, Mario Bavieri, Fausto Barbieri, Sofia Taddei, Eleonora Casalini, Francesco Falco, Filippo Gozzi, Gi Source Type: research

PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry
PD-1/PD-L1 blockade is now a well-established therapeutic strategy in non-small cell lung cancer (NSCLC). Pembrolizumab monotherapy is approved by Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japanese Ministry of Health, Labour and Welfare (MHLW) for first-line treatment in metastatic NSCLC with high PD-L1 expression and lack of a targetable driver mutation [1]. The pembrolizumab companion PD-L1 immunohistochemistry (IHC) uses the antibody 22C3 clone. PD-L1 expression detected as tumor cell membrane staining is semi-quantitatively assessed microscopically. (Source: Lung Cancer)
Source: Lung Cancer - July 31, 2020 Category: Cancer & Oncology Authors: Ju-Yoon Yoon, Rakesh Nayyar, Graeme Quest, Dana Pabedinskas, Prodipto Pal, Ming-Sound Tsao, Joerg Schwock, Hyang-Mi Ko Source Type: research

Baseline Results of the West London lung cancer screening pilot study – Impact of mobile scanners and dual risk model utilisation
The recent publication of the Dutch-Belgian lung-cancer screening trial (Nederlands –Leuvens Longkanker Screenings Onderzoek [NELSON]) [1] corroborates the findings of the earlier United States National Lung Screening Trial (NLST) [2] in confirming the benefits of low-dose CT (LDCT) screening for reducing lung cancer mortality. De Koning et al. report a reduction in lung cancer m ortality of 24 % in males, and 33 % in females at 10 years, achieved through interval LDCT screening compared to a control group [1]. (Source: Lung Cancer)
Source: Lung Cancer - July 31, 2020 Category: Cancer & Oncology Authors: Emily C. Bartlett, Samuel V. Kemp, Carole A. Ridge, Sujal R. Desai, Saeed Mirsadraee, Jaymin B. Morjaria, Pallav L. Shah, Sanjay Popat, Andrew G. Nicholson, Alexandra J. Rice, Simon Jordan, Sofina Begum, Aleksander Mani, Jane Derbyshire, Katie Morris, Mic Source Type: research

Necrolytic Migratory Erythema-like Eruption Associated with Erlotinib in a Patient with Lung Adenocarcinoma
Erlotinib is a tyrosine kinase inhibitor commonly used in patients with lung cancer. While cutaneous manifestations may develop after the use of erlotinib, including acneiform eruption, paronychia, and xerosis, erlotinib-related necrolytic migratory erythema (NME)-like skin eruptions have not been reported [1]. Here, we described a rare case of NME-like skin eruption that developed in a patient with lung cancer treated with erlotinib. (Source: Lung Cancer)
Source: Lung Cancer - July 30, 2020 Category: Cancer & Oncology Authors: Sheng-Hsiang Ma, Cheng-Yuan Li Source Type: research

Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma
Pleural malignant mesothelioma is a representative mesothelial malignant tumor, and the causal relevance of past exposure to asbestos is well recognized. The current World Health Organization (WHO) classification includes three subtypes of mesothelioma: epithelioid, sarcomatoid, and biphasic.1 Epithelioid mesothelioma lesions generally express mesothelial markers such as calretinin, Wilms ’ tumor-1 (WT-1), and podoplanin (D2-40), so antibody panels are useful for diagnosing the condition. On the other hand, sarcomatoid mesothelioma lesions are often negative for some of these antibodies, and therefore the diagnosis m...
Source: Lung Cancer - July 29, 2020 Category: Cancer & Oncology Authors: Yasuhiro Nakashima, Kentaro Inamura, Hironori Ninomiya, Sakae Okumura, Mingyon Mun, Susumu Kirimura, Masashi Kobayashi, Kenichi Okubo, Yuichi Ishikawa Source Type: research

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
The treatment strategy in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is shifting toward newer agents in the first line setting, while the existing roadmap in ROS1(+) NSCLC is not mature yet. The current NCCN recommendations categories alectinib as the preferred 1st line therapy for ALK(+) and crizotinib for ROS1(+) NSCLC. The ALEX 1,2,3 and the ALTA 4 studies indicates better progression free survival (PFS) when choosing second generation ALK tyrosine kinase inhibitors (TKI) as first line therapy compared with crizotinib. (Source: Lung Cancer)
Source: Lung Cancer - July 27, 2020 Category: Cancer & Oncology Authors: Nir Peled, Roni Gillis, Saadettin Kilickap, Patrizia Froesch, Sergei Orlov, Elena Filippova, Umut Demirci, Petros Christopoulos, Irfan Cicin, Fatma Bugdayci Basal, Cengiz Yilmaz, Moiseenko Fedor, Taner Korkmaz, Semra Paydas, Oliver Gautschi, Alisan Zirtil Source Type: research